Clinical Trial Update: SUSTAIN - Study of Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration [Phase 3]

View source ↗

Summary

This update reports the completion and posted results of the Phase 3 SUSTAIN trial evaluating ranibizumab for subfoveal choroidal neovascularization secondary t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Choroidal Neovascularization

Drugs mentioned

• Lucentis (ranibizumab)

Snippet

Sponsor: Novartis | Conditions: Age Related Macular Degeneration, Choroidal Neovascularization | Phase 3 | Status: COMPLETED | Results posted: 2011-01-04